The Effects of Enoximone in Acute Exacerbation COPD
Status:
Not yet recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Introduction:
The pharmacodynamic properties of enoximone could be beneficial for patients with an Acute
Exacerbation COPD (AE-COPD). This research will focus on patients suffering of a severe
AE-COPD and the bronchodilatory and inotropic effects of lower doses of enoximone. The main
objective of the pilot study is to investigate if there is a bronchodilatory effect of
enoximone in patients with AE-COPD. Secondary objective is to investigate a dose
responsiveness in a range between 0.5 and 1.5 mg/kg enoximone.
Methods:
The study design is a prospective interventional non-randomized clinical series study
involving patients admitted and intubated at the Intensive Care Unit (ICU) with an AE-COPD.
Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval. The
primary objective is a reduction in auto-positive end-expiratory pressure (PEEP) after
enoximone compared to baseline. A dose-titration will test for dose dependency. Secondary
objectives are a reduction in ventilator pressures, a reduction in pulmonary artery pressures
and an increase in cardiac output.